Immune responses and clinical outcomes after COVID-19 vaccination in patients with liver disease and liver transplant recipients
Sam M. Murray, Elisa Pose, Melanie Wittner, María‐Carlota Londoño, Golda Schaub, Jonathan Cook, Stavros Dimitriadis, Georgina Meacham, Sophie Irwin, Zixiang Lim, Paul Duengelhoef, Martina Sterneck, Ansgar W. Lohse, Valeria Perez, Palak Trivedi, K Bhandal, Benjamin H. Mullish, Pinelopi Manousou, Nicholas M. Provine, Emma Avitabile, Miles W. Carroll, Tom Tipton, Saoirse Healy, Patrizia Burra, Paul Klenerman, Susanna Dunachie, Barbara Kronsteiner, Agnieszka Katarzyna Macioła, Giulia Pasqual, Virginia Hernández–Gea, Juan Carlos García‐Pagán, Pietro Lampertico, Massimo Iavarone, Pere Ginès, Marc Lütgehetmann, Julian Schulze zur Wiesch, Francesco Paolo Russo, Eleanor Barnes, Eleanor Barnes, Thomas Marjot, Thomas Marjot
Abstract
BACKGROUND & AIMS: Comparative assessments of immunogenicity following different COVID-19 vaccines in patients with distinct liver diseases are lacking. SARS-CoV-2-specific T-cell and antibody responses were evaluated longitudinally after one to three vaccine doses, with long-term follow-up for COVID-19-related clinical outcomes. METHODS: A total of 849 participants (355 with cirrhosis, 74 with autoimmune hepatitis [AIH], 36 with vascular liver disease [VLD], 257 liver transplant recipients [LTRs] and 127 healthy controls [HCs]) were recruited from four countries. Standardised immune assays were performed pre and post three vaccine doses (V1-3). RESULTS: In the total cohort, there were incremental increases in antibody titres after each vaccine dose (p <0.0001). Factors associated with reduced antibody responses were age and LT, whereas heterologous vaccination, prior COVID-19 and mRNA platforms were associated with greater responses. Although antibody titres decreased between post-V2 and pre-V3 (p = 0.012), patients with AIH, VLD, and cirrhosis had equivalent antibody responses to HCs post-V3. LTRs had lower and more heterogenous antibody titres than other groups, including post-V3 where 9% had no detectable antibodies; this was heavily influenced by intensity of immunosuppression. Vaccination increased T-cell IFNγ responses in all groups except LTRs. Patients with liver disease had lower functional antibody responses against nine Omicron subvariants and reduced T-cell responses to Omicron BA.1-specific peptides compared to wild-type. 122 cases of breakthrough COVID-19 were reported of which 5/122 (4%) were severe. Of the severe cases, 4/5 (80%) occurred in LTRs and 2/5 (40%) had no serological response post-V2. CONCLUSION: After three COVID-19 vaccines, patients with liver disease generally develop robust antibody and T-cell responses to vaccination and have mild COVID-19. However, LTRs have sustained no/low antibody titres and appear most vulnerable to severe disease. IMPACT AND IMPLICATIONS: Standardised assessments of the immune response to different COVID-19 vaccines in patients with liver disease are lacking. We performed antibody and T-cell assays at multiple timepoints following up to three vaccine doses in a large cohort of patients with a range of liver conditions. Overall, the three most widely available vaccine platforms were immunogenic and appeared to protect against severe breakthrough COVID-19. This will provide reassurance to patients with chronic liver disease who were deemed at high risk of severe COVID-19 during the pre-vaccination era, however, liver transplant recipients had the lowest antibody titres and remained vulnerable to severe breakthrough infection. We also characterise the immune response to multiple SARS-CoV-2 variants and describe the interaction between disease type, severity, and vaccine platform. These insights may prove useful in the event of future viral infections which also require rapid vaccine development and delivery to patients with liver disease.